Navigation Links
Actuate Therapeutics Announces 9-ING-41 Data Presentation At ASCO Annual Meeting 2020

Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) will be presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May 29th, 2020. Dr. Benedito Carneiro, Brown University’s principal investigator on the 1801 study, will give an oral presentation titled, “Phase I study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3ß) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors” (Abstract #3507). His presentation will be available on May 29th, 2020 at

“Thanks to Dr. Carneiro and our collaborating investigators at US and EU world leading cancer centers, the 1801 Clinical Study has accrued a large diverse cohort of patients and is confirming 9-ING-41’s very favorable safety profile, specifically in heavily pre-treated patients with a wide spectrum of malignancies”, said Ludimila Cavalcante, MD, Lead Medical Affairs at Actuate. “Importantly, 9-ING-41, at therapeutic dose levels, has demonstrated no serious adverse events reported in over 170 patients enrolled on the study to date. Based on encouraging initial results in patients with advanced cancers treated with 9-ING-41, we are now moving to the efficacy stage of the 1801 study starting with a Phase 2 trial of 9-ING-41 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with advanced pancreatic cancer. We are also opening our clinical studies in patients with advanced myelofibrosis and in pediatric oncology patients, the designs of which has been significantly informed by the positive data to date from the 1801 study.”

“9-ING-41 has given us our first opportunity to assess the impact of GSK-3ß modulation in patients with cancer” said Professor Pamela Munster, Principle Investigator on the 1801 study at the University of California, San Francisco. “At a range of doses, both as a single agent and in combination with cytotoxic agents, 9-ING-41 is very well tolerated. Evolving pre-clinical data on its modes of action, anti-fibrotic activity, and immune-modulatory effects are being mirrored by positive clinical data on the 1801 study. We are excited to move 9-ING-41 into efficacy Phase 2 studies and I am particularly interested in exploring its potential in cancers with DNA damage repair gene aberrations”

About Actuate Therapeutics, Inc.
Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and fibrotic diseases. For additional information, please visit the Company’s website at

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Gritstone Oncology Adopts Genedata Biopharma Platform to Accelerate Development of TCR and Bispecific Antibody Therapeutics
2. Cytonus Therapeutics Announces Christopher Thorne as Chairman
3. VetStem Biopharma Enters Pet Cancer Field with Key License from Leading Human Cancer Company, Calidi Biotherapeutics
4. Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland
5. Nativis Announces Name Change To EMulate Therapeutics, Inc.
6. uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
7. RoosterBio Inc. and Tissue Regeneration Therapeutics Inc. Announce Alliance Around Scale-up Manufacturing of Umbilical Cord Tissue Perivascular Cell Technology
8. Cybrexa Therapeutics Expands Scientific Advisory Board Ahead of IND Filing
9. Orbsen Therapeutics' NEPHSTROM Clinical Trial Underway at Four European Union Locations
10. Genedata Announces Aptevo Therapeutics Deploys Genedata Biologics to Streamline Cancer Immunotherapy R&D
11. Spero Therapeutics Acquires Next Generation Antibacterial Candidates from Pro Bono Bio for Treatment of Multidrug-Resistant, Gram-Negative Infections
Post Your Comments:
(Date:8/26/2020)... ... ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, is ... is the most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions made ... three-year revenue growth of 71 percent. , The Inc. 5000 list represents a ...
(Date:8/21/2020)... ... August 20, 2020 , ... NDA Partners Chairman ... Clinical Operations executive with expertise in clinical trial planning and feasibility, regulatory inspection ... Expert Consultant. Throughout his career, Mr. Movahhed has helped design and manage oncology, ...
(Date:8/5/2020)... Fla. (PRWEB) , ... August 05, 2020 , ... Regenative ... cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts ... defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft product ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... 11, 2020 , ... The FSHD Society announced today that ... Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on funding of ... academic research centers in the United States and Europe with expertise in FSHD ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... Jim Corrigan, President and CEO has been named one of the 100 most ... industry sectors, PharmaVoice 100 honorees are selected based on how they have inspired ...
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. has ... be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar ... switches in a push-pull configuration; yielding fast fall time for a capacitive load. ...
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® ... in 16 countries, has reached its 20th anniversary of worldwide use. Introduced in ... at top universities including University of Pennsylvania, University of Michigan, University of Maryland, ...
Breaking Biology Technology: